Slc13a3-KO Mouse
一般名
Slc13a3-KO
製品ID
S-KO-19083
背景情報
C57BL/6JCya
系統ID
KOCMP-114644-Slc13a3-B6J-VB
状況
このマウス系統を論文で使用する場合は、「Slc13a3-KO Mouse(カタログ番号S-KO-19083)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Slc13a3-KO
系統ID
KOCMP-114644-Slc13a3-B6J-VB
遺伝子名
製品ID
S-KO-19083
遺伝子別名
NaC3, NaDC3, SDCT2, NaDC-3
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 2
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000029208
NCBIトランスクリプトID
NM_054055
ターゲット領域
Exon 3
有効領域の大きさ
~1.3 kb
遺伝子研究の概要
Slc13a3, encoding the plasma membrane Na+/dicarboxylate cotransporter 3 (NaDC3), is mainly expressed in the kidney, astrocytes, and choroid plexus. It imports 4-6 carbon dicarboxylates and N-acetylaspartate (NAA) into the cell, playing important roles in multiple biological processes and associated with various pathways [5,7].
In cancer research, gene-targeted mouse models have provided valuable insights. In liver cancer, activation of β-catenin up-regulates Slc13a3, and its silencing in β-catenin-activated liver cancer cells leads to leucine depletion, mTOR inactivation, GSH depletion, and autophagic ferroptosis. Both genetic inhibition of Slc13a3 and a small molecule inhibitor suppress β-catenin-driven hepatocarcinogenesis in mice, suggesting it as a therapeutic target for liver cancers with GOF CTNNB1 mutations [2].
In the tumor microenvironment, deletion of Slc13a3 in tumors or treatment with its inhibitor sensitizes tumors to ferroptosis, curbs tumor progression, and enhances immune checkpoint blockade (ICB) effectiveness as tumor cells uptake itaconate via Slc13a3 from tumor-associated macrophages (TAMs), activating the NRF2-SLC7A11 pathway to escape immune-mediated ferroptosis [1]. Also, Slc13a3 inhibition enhances the efficacy of anti-CTLA-4 immunotherapy in syngeneic mouse tumor models as itaconate transported by Slc13a3 alkylates PD-L1, stabilizing it and promoting tumor immune evasion [4].
In hepatic antibacterial innate immunity, liver-specific deletion of Slc13a3 impairs this immunity both in vivo and in vitro. Itaconate uptake via Slc13a3 induces TFEB-dependent lysosomal biogenesis to improve antibacterial innate immunity in mouse hepatocytes [3].
In Canavan leukodystrophy murine models, astroglial conditional Slc13a3 knockout reversed brain NAA elevation and improved motor function [6].
In conclusion, Slc13a3 is crucial for the transport of specific molecules and is involved in multiple biological processes. Studies using gene knockout or conditional knockout mouse models have revealed its significance in diseases such as cancer, hepatic antibacterial immunity, and Canavan leukodystrophy. These findings provide potential therapeutic targets and new insights into the pathogenesis of these diseases.
References:
1. Lin, Heng, Tison, Kole, Du, Yuheng, Wang, Shaomeng, Zou, Weiping. 2024. Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. In Cancer cell, 42, 2032-2044.e6. doi:10.1016/j.ccell.2024.10.010. https://pubmed.ncbi.nlm.nih.gov/39515327/
2. Zhao, Wennan, Wang, Xue, Han, Lifeng, Chen, Xin, Zhang, Youcai. 2024. SLC13A3 is a major effector downstream of activated β-catenin in liver cancer pathogenesis. In Nature communications, 15, 7522. doi:10.1038/s41467-024-51860-2. https://pubmed.ncbi.nlm.nih.gov/39215042/
3. Chen, Chao, Liu, Caiyun, Sun, Pengkai, Liu, Ping, Li, Xinjian. 2024. Itaconate uptake via SLC13A3 improves hepatic antibacterial innate immunity. In Developmental cell, 59, 2807-2817.e8. doi:10.1016/j.devcel.2024.07.011. https://pubmed.ncbi.nlm.nih.gov/39116875/
4. Fan, Yizeng, Dan, Weichao, Wang, Yuzhao, Wei, Wenyi, Li, Lei. 2025. Itaconate transporter SLC13A3 confers immunotherapy resistance via alkylation-mediated stabilization of PD-L1. In Cell metabolism, 37, 514-526.e5. doi:10.1016/j.cmet.2024.11.012. https://pubmed.ncbi.nlm.nih.gov/39809284/
5. Dewulf, Joseph P, Wiame, Elsa, Dorboz, Imen, Nassogne, Marie-Cécile, Schiff, Manuel. 2019. SLC13A3 variants cause acute reversible leukoencephalopathy and α-ketoglutarate accumulation. In Annals of neurology, 85, 385-395. doi:10.1002/ana.25412. https://pubmed.ncbi.nlm.nih.gov/30635937/
6. Hull, Vanessa L, Wang, Yan, McDonough, Jennifer, Guo, Fuzheng, Pleasure, David. 2024. Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy. In Annals of clinical and translational neurology, 11, 1059-1062. doi:10.1002/acn3.52010. https://pubmed.ncbi.nlm.nih.gov/38282243/
7. Hussain, Syeda Iqra, Muhammad, Nazif, Shah, Salah Ud Din, Wasif, Naveed, Khan, Saadullah. 2023. Structural and functional implications of SLC13A3 and SLC9A6 mutations: an in silico approach to understanding intellectual disability. In BMC neurology, 23, 353. doi:10.1186/s12883-023-03397-y. https://pubmed.ncbi.nlm.nih.gov/37794328/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
